The aims of this study were to evaluate: 1) bone expression of FGF-23 and sclerostin; and 2) their relationships with histologically determined bone turnover parameters and serum levels in patients with various degrees of CKD. The gene discussed is FGF23; the disease is chronic kidney disease.